Status:
COMPLETED
Dexmedetomidine Alleviates Postoperative Delirium After Brain Tumor Resections
Lead Sponsor:
Beijing Tiantan Hospital
Conditions:
Dexmedetomidine
Postoperative Delirium
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Postoperative delirium (POD) is a common complication, and the incidence rate is about 25% in non cardiac surgery. Previous studies have reported that the total incidence of neurological pod ranged fr...
Eligibility Criteria
Inclusion
- Patients undergoing selective frontotemporal tumor resection.
- Age ≥18 years.
- Obtain written informed consent.
Exclusion
- Refusal to provide written informed consent.
- Preoperative severe cognitive impairment (mini-mental state examination, MMSE ≤ 20).
- Allergic to the study drug.
- History of psychotropic drugs within past 30 days.
- Pregnant or lactating women.
- History of traumatic brain injury or neurosurgery.
- Severe bradycardia (heart rate less than 40 beats per minute), sick sinus syndrome or second-to-third degree atrioventricular block.
- Severe hepatic or renal dysfunction.
Key Trial Info
Start Date :
January 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 28 2022
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT04674241
Start Date
January 18 2021
End Date
January 28 2022
Last Update
April 4 2022
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing TianTan Hospital,Capital Medical University
Beijing, Beijing,China, China, 100070
2
PLA General Hospital
Beijing, China, 100853